0.1693
3.42%
-0.006
After Hours:
.1777
0.0084
+4.96%
ReShape Lifesciences Inc. stock is currently priced at $0.1693, with a 24-hour trading volume of 72,742.
It has seen a -3.42% decreased in the last 24 hours and a -3.26% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.173 pivot point. If it approaches the $0.168 support level, significant changes may occur.
Previous Close:
$0.1753
Open:
$0.175
24h Volume:
72,742
Market Cap:
$3.97M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.00264
EPS:
-64.04
Net Cash Flow:
$-17.45M
1W Performance:
-0.29%
1M Performance:
-3.26%
6M Performance:
-32.82%
1Y Performance:
-93.20%
ReShape Lifesciences Inc. Stock (RSLS) Company Profile
Name
ReShape Lifesciences Inc.
Sector
Industry
Phone
949 429 6680
Address
1001 Calle Amanecer, San Clemente
ReShape Lifesciences Inc. Stock (RSLS) Latest News
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
GlobeNewswire Inc.
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
GlobeNewswire Inc.
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
GlobeNewswire Inc.
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
GlobeNewswire Inc.
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
GlobeNewswire Inc.
ReShape Lifesciences Inc. Stock (RSLS) Financials Data
ReShape Lifesciences Inc. (RSLS) Revenue 2024
RSLS reported a revenue (TTM) of $9.81 million for the quarter ending September 30, 2023, a -13.01% decline year-over-year.
ReShape Lifesciences Inc. (RSLS) Net Income 2024
RSLS net income (TTM) was -$26.16 million for the quarter ending September 30, 2023, a +60.61% increase year-over-year.
ReShape Lifesciences Inc. (RSLS) Cash Flow 2024
RSLS recorded a free cash flow (TTM) of -$17.45 million for the quarter ending September 30, 2023, a +22.83% increase year-over-year.
ReShape Lifesciences Inc. (RSLS) Earnings per Share 2024
RSLS earnings per share (TTM) was -$38.77 for the quarter ending September 30, 2023, a +77.99% growth year-over-year.
About ReShape Lifesciences Inc.
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Cap:
|
Volume (24h):